China Independent Clinical Laboratory Industry Report,2013-2015
  • Sep./2013
  • Hard Copy
  • USD $1,700
  • Pages:57
  • Single User License
    (PDF Unprintable)       
  • USD $1,600
  • Code: ZYM046
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,400
  • Hard Copy + Single User License
  • USD $1,900
      
Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clinical laboratory market only values RMB2.5-3 billion, equivalent to 2%-3% of the total revenue of medical diagnosis, much lower than 30% in developed countries.

However, in the context of Chinese medical reform, the cost control of public hospitals, the increasing number of patients that primary medical institutions are confronted with, the rapid development of private hospitals and other factors will greatly boost China independent clinical laboratory industry which will grow at a rate over 40%.

The report focuses on the operation, advantages and characteristics of 10 major independent clinical laboratory companies in China on the basis of an analysis on the development environment, the market situation, the competition pattern, the impact of upstream and downstream as well as the prospect of China independent clinical laboratory industry.

In China, among about 110 laboratories engaged in independent medical diagnosis, top four ones, namely Kingmed Diagnostics, ADICON, DiAn Diagnostics and DaAn Health, master more than 70% domestic market share together, all with the chain integrated diagnostic service mode.

As a giant in China independent clinical laboratory industry, Kingmed Diagnostics has maintained a revenue growth rate of more than 50% in the past five years. It achieved the revenue of over RMB1 billion in 2012 with 21 laboratories, over 13,000 clients (including more than 1,000 Grade-A hospitals) and 1,600 types of inspection services. Moreover, the company has received two rounds of capital injection from Lenovo, and always stood at the leading position of the industry.

ADICON and DiAn Diagnostics are located in the second echelon in the industry.

ADICON targets at the high-end field (including 220 special inspection items), with 15 laboratories, only second to Kingmed Diagnostics. In June 2012, the subsidiary Hefei ADICON became a designated cervical and breast cancer diagnosis institution in Hefei by virtue of the strong and efficient diagnostic service network.

China's first listed independent clinical laboratory enterprise DiAn Diagnostics gained the revenue of RMB414 million from independent medical diagnostic services in 2012, up 52.2% year on year. DiAn Diagnostics shows significant unique competitive advantages, reflected in hierarchical management and "agency + services" business model. As of the end of 2012, DiAn Diagnostics owned 13 independent diagnostic laboratories, and planned to establish 15 Class-A laboratories and 30 Class-B ones by 2016 for the purpose of the overall improvement in the service response speed.
1 Overview of Independent Medical Diagnosis 
1.1 Definition
1.2 Industry Chain

2 Overview of China Independent Clinical Laboratory Industry 
2.1 Policy 
2.1.1 Access Policy
2.1.2 Industrial Policy
2.2 Impact of International Market 
2.2.1 Market Situation
2.2.2 Key Enterprises
2.3 Status Quo 
2.4 Competition Pattern
2.5 Development Prospect and Trend 

3 Upstream and Downstream of China Independent Clinical Laboratory Industry
3.1 Impact of Upstream Market
3.1.1 Market Situation
3.1.2 Competition Pattern
3.2 Impact of Downstream Development
3.2.1 Huge Independent Medical Diagnosis Market
3.2.2 Health Care Reform Propels the Rapid Development of the Independent Medical Diagnosis Market
3.2.3 Diversified Demand Will Promote the Upgrading of the Independent Clinical Laboratory Industry

4 Major Independent Clinical Laboratory Enterprises in China
4.1 Kingmed Diagnostics
4.1.1 Profile
4.1.2 Status Quo and Prospect 
4.2 Hangzhou ADICON 
4.3 DiAn Diagnostics 
4.3.1 Profile
4.3.2 Operation
4.3.3 Business Structure 
4.3.4 Gross Margin 
4.3.5 Clients and Suppliers 
4.3.6 R & D and Investment 
4.3.7 Independent Medical Diagnostic Services
4.3.8 Development Prospect and Trend 
4.4 Da An Gene
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure 
4.4.4 Gross Margin 
4.4.5 Clients and Suppliers 
4.4.6 R & D
4.4.7 Independent Medical Diagnostic Services
4.5 Beijing NYMPHAVN 
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure 
4.5.4 Gross Margin 
4.5.5 Clients 
4.5.6 R & D and Investment 
4.6 CapitalBio 
4.7 Beijing Adinovo 
4.8 Hangzhou Zhiyuan 
4.9 Kindstar Global (Beijing)
4.10 Deyi Diagnostics

Schematic Diagram of Independent Medical Diagnostic Industry Chain
Comparison between China and the U.S. in Medical Diagnosis Providers
Relevant Policies of China Independent Medical Diagnostic Industry, 2010-2012
Market Share of the U.S. Independent Medical Inspection Industry by Item 
U.S. Medical Inspection Market Share (by Provider)
Revenue and Operating Profit of Quest Diagnostics, 2007-2013
Revenue Structure of Quest Diagnostics (by Business), 2011-2012
Major M & A Events of Quest Diagnostics, 2006-2013
Sales and Operating Profit of Labcorp, 2007-2013 
Revenue of Labcorp (by Business), 2009-2013 
Major M & A Events of Labcorp, 2007-2012
Comparison between Massachusetts General Hospital and One Chinese Grade-A Hospital in Top Five Outbound Inspection Items
Basic Characteristics and Market Share of Major Independent Clinical Laboratory Enterprises in China, by the end of 2012
Market Scale and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2015E
Market Scale and Growth Rate of In Vitro Diagnostic Reagents in China, 2007-2015E
Structure of In Vitro Diagnostic Reagents in China, 2012
Chinese In Vitro Diagnostic Reagent Market Segments, 2012
Business and Inspection Revenue of Medical Institutions in China, 2010
Number of Patients of Hospitals and Primary Health Care Institutions in China, 2008-2012
Number of Public and Private Hospitals in China, 2008-2012
Revenue and YoY Growth Rate of Kingmed Diagnostics, 2008-2012
Distribution and Establishment Time of Independent Medical Laboratories of Hangzhou ADICON
Layout of Independent Diagnostic Laboratories of DiAn Diagnostics, by the end of 2012
Revenue and Profit of DiAn Diagnostics, 2008-2013 
Revenue and Net Income of Top Five Subsidiaries of DiAn Diagnostics, 2011-2012
Revenue of DiAn Diagnostics (by Business), 2008-2013 
Revenue Structure of DiAn Diagnostics (by Business), 2008-2013 
Revenue of DiAn Diagnostics (by Region), 2008-2011
Revenue of DiAn Diagnostics (by Region), 2011-2013
Gross Margin of DiAn Diagnostics (by Business), 2008-2013 
Revenue of DiAn Diagnostics from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of DiAn Diagnostics, 2010-2013
Procurement of DiAn Diagnostics from Top 5 Suppliers and % of Total Procurement, 2008-2012 
Name List and Procurement of Top 5 Suppliers of DiAn Diagnostics, 2009-2011 
R&D Costs and % of Total Revenue of DiAn Diagnostics, 2008-2013
Revenue and Gross Margin of Independent Diagnostic Business of DiAn Diagnostic, 2008-2013
Revenue and Gross Margin of Independent Diagnostic Business of DiAn Diagnostic (by Product), 2008-2012
Revenue Percentage of Independent Diagnostic Business of DiAn Diagnostics (by Client), 2010-2012
Revenue and Operating Income of DiAn Diagnostics, 2012-2015E 
Revenue and Profit of Da An Gene, 2008-2013
Revenue of Da An Gene (by Product), 2008-2012 
Revenue Structure of Da An Gene (by Region), 2008-2012 
Gross Margin of Da An Gene (by Product), 2008-2012 
Name List and Revenue Contribution of Top 5 Clients of Da An Gene, 2012
Name List and Procurement of Top 5 Suppliers of Da An Gene, 2012
R&D Costs and % of Total Revenue of Da An Gene, 2010-2012
Revenue and Gross Margin of Medical Laboratory Services of Da An Gene, 2008-2012
Registered Capital, Revenue and Net Income of Medical Laboratory Subsidiaries of Da An Gene, 2012 
Revenue and Profit of NYMPHAVN, 2009-2013 
Revenue of NYMPHAVN (by Product), 2009-2013 
Revenue of NYMPHAVN (by Region), 2010-2012
Gross Margin of NYMPHAVN (by Product), 2009-2013 
NYMPHAVN’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2013
Name List and Revenue Contribution of NYMPHAVN’s Top 5 Clients, 2012-2013
R&D Costs and % of Total Revenue of NYMPHAVN, 2009-2012 
Some Strategic Copartners of Adinovo
Major Events of Kindstar Global 

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号